Literature DB >> 31336199

Seroprevalence of Helicobacter pylori Infection in a National Cohort of Veterans With Noncardia Gastric Adenocarcinoma.

Shria Kumar1, David C Metz2, David E Kaplan3, David S Goldberg2.   

Abstract

Conventional teaching is that Helicobacter pylori infection is required for the development of non-cardia gastric adenocarcinoma (NCGC) through a sequence of atrophic gastritis, intestinal metaplasia, dysplasia, and finally, cancer.1-3 However, studies have not demonstrated a 100% rate of H pylori infection in gastric malignancy, hypothesized to be due to false negatives, gastric atrophy leading to apparent loss of infection, and inclusion of cardia, nonintestinal cancers.1-3.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31336199      PMCID: PMC6980451          DOI: 10.1016/j.cgh.2019.07.026

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

Review 1.  Helicobacter pylori Infection.

Authors:  Sheila E Crowe
Journal:  N Engl J Med       Date:  2019-03-21       Impact factor: 91.245

2.  Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update.

Authors:  Leah L Zullig; Kellie J Sims; Rebecca McNeil; Christina D Williams; George L Jackson; Dawn Provenzale; Michael J Kelley
Journal:  Mil Med       Date:  2017-07       Impact factor: 1.437

Review 3.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.

Authors: 
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 4.  Helicobacter pylori and gastric carcinogenesis.

Authors:  P Correa
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

5.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

Authors:  A Nomura; G N Stemmermann; P H Chyou; I Kato; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

6.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

Review 7.  The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer.

Authors:  Steven F Moss
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-12-27

8.  Must-Have Knowledge about the Helicobacter pylori-Negative Gastric Cancer.

Authors:  Jeong Ho Kim; Dae Young Cheung
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

  8 in total
  5 in total

1.  Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study.

Authors:  Shria Kumar; David C Metz; Susan Ellenberg; David E Kaplan; David S Goldberg
Journal:  Gastroenterology       Date:  2019-10-22       Impact factor: 22.682

2.  Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration.

Authors:  Shria Kumar; David C Metz; David E Kaplan; David S Goldberg
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

3.  Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia.

Authors:  Aaron P Thrift; Andre G Jove; Yan Liu; Mimi C Tan; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2022-01-01       Impact factor: 3.062

4.  Follow-up analysis and histopathological study of gastric mucosa in patients with Helicobacter pylori infection.

Authors:  Guang Zhao; Zhishang Zhang; Baohui Li; Silin Huang; Wensi Li; ChaoYa Zhu; Bo Jiang; Songmao He; Yangkun Wang; Su'nan Wang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

5.  The association of Helicobacter pylori with pancreatic cancer.

Authors:  Shria Kumar; David C Metz; David E Kaplan; David S Goldberg
Journal:  GastroHep       Date:  2020-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.